WAVEMAN · COMPANY

SGIOF · Shionogi & Co Ltd

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

SGIOF

Name: SHIONOGI & CO LTD (SGIOF) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

SHIONOGI & CO LTD

SERVICES · AMERICAN DEPOSITARY RECEIPTS · CIK 0001281721

SEC FILINGS☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

XBRL, annual

NET MARGIN

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

1 fund added or opened last quarter

below 98% of Services

REVENUE

no revenue reported in any filing

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

no share repurchases reported

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

Federal contracts worth $156.1M were awarded in the last 180 days.

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows 1 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

YELP NRDY CRAI CAR LINC BOXL PRDO SCI R APEI COE DLPN

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for SHIONOGI & CO LTD in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

no insider purchases or sales on record

0 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see the full history, the screener and CSV export, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

HOURGLASS CAPITAL, LLC

87,800.0 sh

$749.8K

RHUMBLINE ADVISERS

82,033.0 sh

$700.6K

Sterling Capital Management LLC

53,169.0 sh

$456.2K

GAMMA Investing LLC

15,545.0 sh

$132.8K

PNC Financial Services Group, Inc.

11,736.0 sh

$100.2K

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

AAM Todd International Intrinsic Value ETF

$371.8K POSITION · AS OF 2026-04-30

1.3%

SP Funds S&P World (ex-US) ETF

$129.3K POSITION · AS OF 2026-04-30

0.1%

ActivePassive International Equity ETF

$49.9K POSITION · AS OF 2026-02-28

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 60 registered trials, 11 still enrolling or running — a status change here is dated weeks before the press release

Phase 1

2 ACTIVE

Phase 2

5 ACTIVE

Phase 3

2 ACTIVE

Phase 4

0 ACTIVE

Not applicable

0 ACTIVE

Multi-phase

2 ACTIVE

What changed recently

Study of Secutrelvir in Participants With COVID-19

2026-09-03 · Not Yet Recruiting → Recruiting

Phase 3

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Government contracts

USASpending.gov · total award ceilings over the contract's life, including awards won through subsidiaries — not annual revenue

Department Of Health And Human Services

LATE-STAGE DEVELOPMENT, FDA MARKETING AUTHORIZATION, PROCUREMENT, AND STOCKPILE OF ANTIBIOTICS FOR T · 2026-04-06

$156.1M

FEDERAL AWARDS ≥ $25M IN THE LAST 90 DAYS · MATCHED VIA SAM.GOV PARENT REGISTRY